This report analyzes the disruptive themes that have driven M&A activity in Q1 2025 in the Healthcare Sector.
The global healthcare market in Q1 2025 witnessed deals worth $91 billion, a decline of 10% compared to Q1 2024. The sector recorded deal value worth $75 billion mega-deals (defined as any deal valued at more than $1 billion), a decrease of 10% compared to Q1 2024.
The global healthcare market in Q1 2025 witnessed deals worth $91 billion, a decline of 10% compared to Q1 2024. The sector recorded deal value worth $75 billion mega-deals (defined as any deal valued at more than $1 billion), a decrease of 10% compared to Q1 2024.
Scope
- This report provides an overview of merger and acquisition activity globally in Q1 2025 in Healthcare Sector
- It identifies the themes driving most notable to deals announced in Q1 2025 in the Healthcare Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in Healthcare sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Executive Summary
- Review of the Healthcare M&A Market - Q1 2025
- Top Healthcare M&A Deals by Sector - Q1 2025
- Healthcare M&A Deals Analysis by Geography - Q1 2025
- Top Themes Driving Healthcare M&A Activity - Q1 2025
- Appendix 1: Deal Selection Criteria
- Appendix 2: Top Themes for 2025 in Healthcare
- Appendix 3: Thematic Research Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- JIC PE Co-Investment Fund No 1
- JIC PE Fund No 1
- KKR Asian Fund IV
- TK Corporation, Inc.
- Topcon Corp - Management Team
- Sanofi
- Advanced Instruments Inc
- The Doctors Company
- Taiho Pharmaceutical Co Ltd
- AstraZeneca Plc
- Sycamore Partners
- Jazz Pharmaceuticals Plc
- Thermo Fisher Scientific Inc
- Novartis AG
- Bain Capital LP
- Zimmer Biomet Holdings Inc
- Lantheus Holdings Inc
- Pure Health Holding PJSC
- Johnson & Johnson
- Eli Lilly and Co
- GSK plc
- Gilead Sciences Inc
- Boston Scientific Corp
- Eagle 1 Merger Sub Inc
- Topcon Corp
- Dren Bio
- Nova Biomedical Corp
- ProAssurance Corp
- Araris Biotech AG
- EsoBiotec SA
- Walgreens Boots Alliance Inc
- Chimerix Inc
- Solventum
- Anthos Therapeutics Inc
- Mitsubishi Tanabe Pharma Corp
- Paragon 28 Inc
- Evergreen Theragnostics Inc
- Hellenic Healthcare Group
- Intra-Cellular Therapies Inc
- Scorpion Therapeutics
- IDRx Inc
- Leo Pharma
- Bolt Medical Inc
- Inari Medical Inc
